COST-EFFECTIVENESS MODEL COMPARING EXPANDED UMBILICAL CORD BLOOD TRANSPLANTS WITH OTHER HSCT STRATEGIES FOR PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES

Author(s)

Tremblay G1, Dolph M1, Sauvageau G2, Cohen S2
1Purple Squirrel Economics, New York, NY, USA, 2Maisonneuve Hospital, Montreal, QC, Canada

OBJECTIVES: A cost-effectiveness model was developed to compare UM171-expanded UCB (E-UCB) to unexpanded UCB (UCB) and unrelated donor transplant (URD) from a Canadian payer perspective.

METHODS: A lifetime-horizon Markov model was developed to evaluate various stem cell sources in patients with haematological malignancies requiring stem cell transplantation (SCT). Health states included: Diagnosis, Pre-progression (SCT recovery), Post-SCT (without GVHD), Post-SCT (with GVHD), and Graft failure/Relapse. UCB and URD estimation of patients transitioning to each health state was derived from published literature (pooled Kaplan-Meier data) and extrapolated using exponential functional forms. E-UCB efficacy data were based on the Kaplan-Meier estimator function derived from the patient level data. Model utilities varied by health state and were based on SCT-specific literature and included complication disutility. Resource utilization and cost calculations associated with each SCT source included costs of SCT, routine medical care, complications (acute and chronic GVHD, infection, and veno-occlusive disease), indirect and mortality (end of life) costs. The primary economic endpoints assessed were life years (LYs) and quality-adjusted life years (QALYs).

RESULTS: When published data were applied in the economic model, E-UCB showed economic dominance over both UCB and URD, with 1.50 and 1.46 LYs gained, respectively, and 1.23 and 1.19 QALYs gained, respectively. The total cost of treating one patient with E-UCB was estimated at $232,842, compared with $291,501 for UCB and $237,355 for URD over a lifetime horizon. While treatment cost was the highest for E-UCB, these costs were offset by lower relapse and GVHD costs in the E-UCB arm resulting in lower overall costs. Deterministic and probabilistic sensitivity analyses generally showed consistency with base case findings.

CONCLUSIONS: E-UCB appeared to be cost-saving and associated with a QALYs gain when compared to UCB and URD. Sensitivity analyses supported the findings and contributed to the robustness of the economic case.

Conference/Value in Health Info

2019-05, ISPOR 2019, New Orleans, LA, USA

Value in Health, Volume 22, Issue S1 (2019 May)

Code

PCN49

Topic

Clinical Outcomes, Economic Evaluation

Topic Subcategory

Comparative Effectiveness or Efficacy, Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×